EZH2 and prostate cancer: miR-101/EZH2 was found to be deregulated in several other types of cancer, including prostate cancer [30], bladder transitional cell carcinoma [31], gastric cancer [37], and described to strongly correlate with migration, invasion, and metastasis [30,37].